Lupus Anticoagulant and Complement C4 Consumption in Antiphospholipid Antibody Testing: Disentangling Inflammation From Autoimmunity.

INTRODUCTION Antiphospholipid antibodies (aPL) define the laboratory criteria for antiphospholipid syndrome (APS), but their relationships with complement consumption, inflammation, and modifiers such as sex remain uncertain. Our central hypothesis was that C4 consumption represents a more specific indicator of immune-complex-driven autoimmunity than composite complement definitions or CRP, which more often reflect nonspecific inflammatory activation. METHODS We retrospectively analyzed 1260 patients tested for lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I (anti-β2GPI), with complement (C3, C4) and C-reactive protein (CRP) available in subsets. This retrospective, fully anonymized laboratory study was approved by the Institutional Review Board. Patients were grouped into eight serological phenotypes. Multivariable logistic regression examined associations with low complement, low C4, and CRP > 1.0 mg/dL, adjusting for sex and inpatient status. Principal component analysis (PCA) identified four components explaining ~86% of variance; clustering was exploratory. RESULTS Low C4 was most strongly associated with LA + aCL and triple-positive profiles and showed good discrimination (AUC 0.84), whereas composite definitions of low complement were less informative (AUC 0.73). Anti-β2GPI-only positivity was linked only to the composite low complement outcome. Low complement occurred more frequently in women. CRP elevation was mainly associated with inpatient status (aOR = 3) and was more common in men, with weaker associations observed for LA-only and multi-positive profiles. The CRP model showed only fair discrimination (AUC 0.68). CONCLUSIONS C4 showed the strongest association in this dataset, whereas CRP largely reflected nonspecific inflammation, especially in hospitalized men. Observed sex-associated patterns were present, with women more often showing complement consumption and men more often showing CRP elevations. These findings indicate that C4 showed a clearer analytical signal than composite definitions, while CRP should be interpreted cautiously. Prospective studies with linked clinical outcomes are needed for validation.

• Publication year

  2026

• Venue

  International Journal of Laboratory Hematology

• Publication date

  2026-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ijlh.70075PMID 41699828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management.

  2023cited by this paper
• Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

  2020cited by this paper
• Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

  2020cited by this paper
• EULAR recommendations for the management of antiphospholipid syndrome in adults

  2019cited by this paper
• SciPy 1.0: fundamental algorithms for scientific computing in Python

  2019cited by this paper
• Complement in the Pathophysiology of the Antiphospholipid Syndrome

  2019cited by this paper
• Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH

  2018cited by this paper
• Antiphospholipid syndrome

  2018cited by this paper
• Principal component analysis: a review and recent developments

  2016cited by this paper
• Sex differences in immune responses

  2016cited by this paper
• The antiphospholipid syndrome: still an enigma.

  2015cited by this paper
• The global anti-phospholipid syndrome score in primary APS.

  2015cited by this paper
• Antiphospholipid syndrome.

  2013cited by this paper
• Standardization of antiphospholipid antibody assays. Where do we stand?

  2012cited by this paper
• Scikit-learn: Machine Learning in Python

  2011cited by this paper
• Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome

  2010cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• Complement activation in patients with primary antiphospholipid syndrome

  2008cited by this paper
• What does minor elevation of C-reactive protein signify?

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

  2003cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• C-reactive protein: a critical update.

  2003cited by this paper
• A solution to the problem of separation in logistic regression

  2002cited by this paper
• Antiphospholipid Antibodies and Pregnancy

  1999cited by this paper
• Bias reduction of maximum likelihood estimates

  1993cited by this paper

• No citing papers are available for this paper.